1. Home
  2. NUVL vs WAY Comparison

NUVL vs WAY Comparison

Compare NUVL & WAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVL
  • WAY
  • Stock Information
  • Founded
  • NUVL 2017
  • WAY 1999
  • Country
  • NUVL United States
  • WAY United States
  • Employees
  • NUVL N/A
  • WAY N/A
  • Industry
  • NUVL Biotechnology: Pharmaceutical Preparations
  • WAY
  • Sector
  • NUVL Health Care
  • WAY
  • Exchange
  • NUVL Nasdaq
  • WAY Nasdaq
  • Market Cap
  • NUVL 5.6B
  • WAY 6.8B
  • IPO Year
  • NUVL 2021
  • WAY 2024
  • Fundamental
  • Price
  • NUVL $74.61
  • WAY $39.98
  • Analyst Decision
  • NUVL Strong Buy
  • WAY Strong Buy
  • Analyst Count
  • NUVL 8
  • WAY 12
  • Target Price
  • NUVL $115.50
  • WAY $41.45
  • AVG Volume (30 Days)
  • NUVL 548.5K
  • WAY 2.0M
  • Earning Date
  • NUVL 05-08-2025
  • WAY 04-30-2025
  • Dividend Yield
  • NUVL N/A
  • WAY N/A
  • EPS Growth
  • NUVL N/A
  • WAY N/A
  • EPS
  • NUVL N/A
  • WAY 0.15
  • Revenue
  • NUVL N/A
  • WAY $975,192,000.00
  • Revenue This Year
  • NUVL N/A
  • WAY $8.84
  • Revenue Next Year
  • NUVL N/A
  • WAY $9.35
  • P/E Ratio
  • NUVL N/A
  • WAY $260.84
  • Revenue Growth
  • NUVL N/A
  • WAY 18.25
  • 52 Week Low
  • NUVL $55.54
  • WAY $20.26
  • 52 Week High
  • NUVL $113.51
  • WAY $48.11
  • Technical
  • Relative Strength Index (RSI)
  • NUVL 54.31
  • WAY N/A
  • Support Level
  • NUVL $70.25
  • WAY N/A
  • Resistance Level
  • NUVL $75.97
  • WAY N/A
  • Average True Range (ATR)
  • NUVL 3.09
  • WAY 0.00
  • MACD
  • NUVL 0.13
  • WAY 0.00
  • Stochastic Oscillator
  • NUVL 79.92
  • WAY 0.00

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About WAY Waystar Holding Corp. Common Stock

Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.

Share on Social Networks: